随着时间的推移,帕金森病中动作震的变化:临床和神经成像相关联
Kevin R E van den Berg1,2, Martin E Johansson1,2, Michiel F Dirkx1,2
1Donders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Nijmegen, The Netherlands.
Movement disorders : official journal of the Movement Disorder Society
|December 16, 2024
概括
帕金森病 (PD) 的严重程度随着时间的推移而有所不同,随着大脑缩与运动症状相关联,动作的减少. 了解这些不同的轨迹是PD管理的关键.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 医疗成像医学成像
背景情况:
- 帕金森病 (PD) 呈现出各种运动症状,这些症状随着时间的推移而逐渐演变.
- 虽然往往出现在早期,但它的进展是不同的,不像布拉迪基尼西亚和刚性.
- 对于PD中这些独特的症状轨迹的潜在大脑机制在很大程度上是未知的.
研究的目的:
- 为了检查帕金森病的纵向变化,与布拉迪基尼西亚和刚性相比.
- 为了确定震进展是否与特定的震相关区域的结构性大脑变化相关.
主要方法:
- 利用了个性化帕金森计划的数据,这是一项为期2年的纵向研究,对520名PD患者和60名对照进行了研究.
- 使用混合效应模型通过MRI分析临床进展 (震,勃拉迪基尼西亚,刚性) 和灰质变化.
- 研究了症状严重程度和大脑结构变化之间的关联,这些变化发生在大脑 - 丘脑 - 皮质电路,皮和整个大脑中.
主要成果:
- 布拉迪基尼西亚和性在两年内恶化;休息震保持稳定,而姿势和运动震的严重程度下降.
- 姿势和运动震的减少与与震相关的大脑区域的缩有关,尽管不完全如此.
- 结构性大脑变化与震进展相比,与布拉迪基尼西亚和刚性相比,显示出相反的相关性.
结论:
- 动作震 (姿势和运动) 是帕金森病的早期症状,随着疾病的进展而减弱.
- 特定区域的纵向脑缩与震进展相反相关,但与勃拉迪基尼西亚和刚性相对正相关.
- 这些发现突出了帕金森病中不同运动症状的独特的神经生物学轨迹.
关键词:
帕金森 帕金森症候群缩性缩 (英语:Atrophy atrophy) 是一种损伤.在纵向的长度上.这是一个渐进的过程.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,更多相关视频
相关概念视频
01:15Parkinson's Disease: Overview
476
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
476
01:24Parkinson's Disease: Treatment
216
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
216
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:26Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
01:22Alzheimer's Disease: Treatment
162
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
162